Stock comparison
Genmab A/S
InMode
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
INMD
InMode
Market cap
$870.55M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | INMD | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 56C | GMAB |
| Benjamin Graham | 64C | 52C | GMAB |
| Philip Fisher | 48D | 46D | GMAB |
| Peter Lynch | 25F | 24F | GMAB |
| Joel Greenblatt | 76B | 27F | GMAB |
| Charlie Munger | 68C | 58C | GMAB |
| Terry Smith | 71C | 59C | GMAB |
Side-by-side metrics
| Metric | GMAB | INMD |
|---|---|---|
| Market cap | $16.5B | $870.55M |
| P/E (TTM) | 6.2x | 10.0x |
| EV/EBIT | 12.0x | 5.6x |
| ROIC (TTM) | 43.78% | 10.11% |
| Gross margin | 93.88% | 77.84% |
| Net margin | 18.23% | 23.27% |
| Revenue CAGR 5y | -18.45% | 0.89% |
| EPS CAGR 5y | -23.48% | -8.07% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $870.55M+95%
- ROIC (TTM)43.78%vs 10.11%+77%
- P/E (TTM)6.2xvs 10.0x+38%
- Gross margin93.88%vs 77.84%+17%
INMD leads on
- Revenue CAGR 5y0.89%vs -18.45%+105%
- Debt / Equity0.0xvs 0.1x+90%
- EPS CAGR 5y-8.07%vs -23.48%+66%
- EV/EBIT5.6xvs 12.0x+53%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.